Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
| Index | Nasdaq Biotechnology |
| Investment focus | Equity, United States, Health Care |
| Fund size | EUR 712 m |
| Total expense ratio | 0.35% p.a. |
| Replication | Physical (Optimized sampling) |
| Legal structure | ETF |
| Investment approach | Long-only |
| Sustainability | No |
| Fund currency | USD |
| Currency risk | Currency unhedged |
| Volatility 1 year (in EUR) | 19.12% |
| Inception/ Listing Date | 19 October 2017 |
| Distribution policy | Accumulating |
| Distribution frequency | - |
| Fund domicile | Ireland |
| Fund Provider | iShares |
| Fund Structure | Open-ended Investment Company (OEIC) |
| UCITS compliance | Yes |
| Administrator | State Street Fund Services (Ireland) Limited |
| Investment Advisor | |
| Custodian Bank | State Street Custodial Services (Ireland) Limited |
| Revision Company | Deloitte |
| Fiscal Year End | 31 May |
| Swiss representative | BlackRock Asset Management Schweiz AG |
| Swiss paying agent | State Street Bank International GmbH, Munich, Zurich Branch |
| Germany | 30% tax rebate |
| Switzerland | ESTV Reporting |
| Austria | Tax Reporting Fund |
| UK | UK Reporting |
| Italy | 26.0% |
| Indextype | Total return index |
| Swap counterparty | - |
| Collateral manager | Bank of New York Mellon|Euroclear|JP Morgan|State Street Bank |
| Securities lending | Yes |
| Securities lending counterparty | Barclays Bank Plc|Barclays Capital Securities Ltd.|BNP Paribas Arbitrage SNC|BNP Paribas SA|Citigroup Global Markets Ltd|Citigroup Inc|Credit Suisse Securities (Europe) Ltd.|Deutsche Bank AG|Goldman Sachs International|HSBC Bank Plc|J.P. Morgan Securities Plc|JP Morgan Chase & Co|Macquarie Bank Limited|Merrill Lynch International|Morgan Stanley & Co. International Plc|Nomura International Plc|Skandinaviska Enskilda Banken AB|Societe Generale SA|The Bank of Nova Scotia|UBS AG |
| Gilead Sciences, Inc. | 7.73% |
| Amgen, Inc. | 7.49% |
| Vertex Pharmaceuticals | 7.42% |
| Regeneron Pharmaceuticals, Inc. | 6.44% |
| Alnylam Pharmaceuticals | 3.52% |
| Insmed | 2.83% |
| Biogen, Inc. | 2.16% |
| United Therapeutics | 2.09% |
| argenx | 1.66% |
| Royalty Pharma | 1.65% |
| United States | 79.85% |
| Bermuda | 1.59% |
| Ireland | 1.52% |
| Other | 17.04% |
| Health Care | 85.52% |
| Consumer Staples | 0.01% |
| Other | 14.47% |
| YTD | +5.66% |
| 1 month | +2.61% |
| 3 months | +0.27% |
| 6 months | +2.19% |
| 1 year | +41.48% |
| 3 years | +36.56% |
| 5 years | +34.11% |
| Since inception (MAX) | +77.01% |
| 2025 | +17.44% |
| 2024 | +5.43% |
| 2023 | +0.53% |
| 2022 | -5.02% |
| Volatility 1 year | 19.12% |
| Volatility 3 years | 20.12% |
| Volatility 5 years | 22.34% |
| Return per risk 1 year | 2.16 |
| Return per risk 3 years | 0.53 |
| Return per risk 5 years | 0.27 |
| Maximum drawdown 1 year | -6.40% |
| Maximum drawdown 3 years | -25.56% |
| Maximum drawdown 5 years | -30.93% |
| Maximum drawdown since inception | -30.93% |
| Listing | Trade Currency | Ticker | Bloomberg / iNAV Bloomberg Code | Reuters RIC / iNAV Reuters | Market Maker |
|---|---|---|---|---|---|
| gettex | EUR | 2B70 | - - | - - | - |
| Stuttgart Stock Exchange | EUR | 2B70 | - - | - - | - |
| Bolsa Mexicana de Valores | MXN | - | BTEC1N MM | BTEC1N.MX | |
| London Stock Exchange | USD | BTEC | BTEC LN INAVBTEU | BTEC.L 0WXSINAV.DE | |
| London Stock Exchange | GBP | BTEK | BTEK LN INAVBTEU | BTEK.L 0WXSINAV.DE | |
| SIX Swiss Exchange | USD | BTEC | BTEC SE INAVBTEU | BTEC.S 0WXSINAV.DE | |
| XETRA | EUR | 2B70 | 2B70 GY INAVBTEE | BTEC.DE 0WXNINAV.DE |
| Fund name | Fund Size in m € (AuM) | TER p.a. | Distribution | Replication |
|---|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) | 47 | 0.35% p.a. | Distributing | Sampling |